ASX 200 shares vs. property: Which delivered the best growth in 2023?

When we compare the capital growth rate of ASX 200 shares vs. property in 2023, it's a dead heat at 8.1%.

The S&P/ASX 200 Index (ASX: XJO) rose from a closing value of 7,020.1 points on the last trading day of 2022 to a closing value of 7,590.8 points on the last trading day of 2023, delivering an 8.1% gain.

Meantime, CoreLogic's national Home Value Index, which incorporates all types of dwellings across the country, also rose by 8.1%.

But if we dig deeper and look at the capital growth rates of the top five ASX 200 shares vs. the capital city and regional property markets, we see a major divergence in the numbers.

Let's take a look.

Best performing property markets of 2023

Here we compare the capital growth of dwellings in the city and regional property markets in 2023.

Best performing ASX 200 shares of 2023

Here we compare the capital growth of the top five ASX 200 shares in 2023.

My Fool colleague James reports on the key drivers for these particular ASX 200 shares in 2023.

If you're considering a new investment in shares vs. property, check out our article on the opportunities of 2024.

mid-cap healthcare stocks. However, those that achieved material commercial milestones have generated positive shareholder returns in the last six months (NEU, DXB, 4DX and PME). With many companies currently trading at depressed valuations, there are stock picking opportunities for those with solid balance sheets to ride out the cyclical downturn and clear catalysts to drive momentum.The new class of GLP-1/GIP drugs continue to dominate news flow for their impact on weight loss and other health outcomes (e.g. lowering cardiovascular events). There is little doubt these drugs will form one of the biggest selling classes to date, with both Novo Nordisk and Eli Lilly unable to keep up with demand. ASX large-cap healthcare companies, including RMD and CSL were sold off as investors drew read throughs for what these drugs could mean for long term demand growth. Fortunately there were no adverse impacts on companies in our coverage and data suggests the sell off in large cap stocks has been overdone in any case